Zhangyun Fang - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Zhangyun Fang

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Journal of Medicinal Chemistry|January 23, 2026

Design, Synthesis, and Evaluation of a Potent and Selective ROCK2 Inhibitor for Atopic Dermatitis TreatmentChuru Mao, Shuai Zhan, Zhangyun Fang, et al.

European Journal of Medicinal Chemistry|January 16, 2026

Discovery of an orally bioavailable pyridone-based BRD4 inhibitor with potent antitumor efficacy in colorectal cancerZhangyun Fang, Shuai Zhan, Churu Mao, et al.

Journal of Medicinal Chemistry|November 11, 2024

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor ImmunityChuru Mao, Jiebin Fang, Shijie Zou, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Journal of Medicinal Chemistry|January 23, 2026

Design, Synthesis, and Evaluation of a Potent and Selective ROCK2 Inhibitor for Atopic Dermatitis TreatmentChuru Mao, Shuai Zhan, Zhangyun Fang, et al.

European Journal of Medicinal Chemistry|January 16, 2026

Discovery of an orally bioavailable pyridone-based BRD4 inhibitor with potent antitumor efficacy in colorectal cancerZhangyun Fang, Shuai Zhan, Churu Mao, et al.

Journal of Medicinal Chemistry|November 11, 2024

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor ImmunityChuru Mao, Jiebin Fang, Shijie Zou, et al.

Pageof 1